Institute of Cancer Research (ICR)

PhD studentships

Institute of Cancer Research (ICR)

London, United Kingdom

Our next big discovery could be you

The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes.
We are committed to attracting and developing the best minds in the world to join us in our mission—to make the discoveries that defeat cancer.
We’re searching for the brightest minds in cancer research

We are offering 24 fully-funded PhD studentships across a range of scientific disciplines including the biological sciences, physics, engineering, chemistry, mathematics, statistics and epidemiology, and computational science.

Please see icr.ac.uk/phds for details on how to apply

Applications close 17 November 2019

Applications are invited from talented graduates or final-year undergraduates who hold or expect to gain a first- or upper second-class honours degree or equivalent, or a masters degree, in a relevant subject. Successful candidates will undertake a four-year research training programme under the guidance of a supervisory team of our world-class researchers, starting in October 2020. The ICR is a college of the University of London and awards degrees of the University.

Funding for our projects comes from the ICR, CRUK, NIHR, Oracle, Sarcoma UK and MRC (with partners Merck and AstraZeneca). Our students receive an annual stipend, currently £21,000 per annum, as well as having fees and project costs paid for the four-year duration.

Physics and Engineering

Dr Dimitra Darambara
The development and implementation of Multi-Spectral CT imaging techniques and artificial intelligence methods within stereotactic radiosurgery treatment planning for oligometastases in the brain and intracranial meningiomas

Dr Emma Harris
Enhancement of radiation induced cell death using ultrasound stimulated microbubbles

Dr Simon Robinson
Advanced functional MRI for the characterisation of paediatric glioma and its response to therapy

Chemistry

Dr Gurdip Bhalay
Novel probes for investigating the tumour microenvironment and tissue targeting

Professor Ian Collins and Dr Sebastian Guettler
A fragment-based approach to identify protein-protein interaction inhibitors of Shelterin complex assembly

Dr Swen Hoelder
In-silico approaches to enable optimisation of small molecule binding by perturbing and interacting with water networks.

Mathematics and Computer Sciences

Dr Matthew Blackledge
Leveraging state-of-the-art methods in Artificial Intelligence and medical imaging for automated response evaluation and prediction of soft-tissue sarcomas to systemic treatment.

Dr Paul Huang
Integrative computational analysis of molecular and clinical data to dissect heterogeneity of therapy response in sarcomas

Professor Christina Yap
Development and Implementation of Efficient Adaptive Designs in Early Phase Oncology Trials for Targeted Agents

Biological Sciences

Dr Claudio Alfieri
Structure and molecular function of the DREAM complex in gene expression programs of cellular quiescence

Dr Jyoti Choudhary
Characterising the immunopeptidome by proteogenomics and elucidating their associated immune response in head and neck cancer

Dr Norman Davey
Investigating the druggability of the motif-mediated interactome with peptide PROTACs

Dr Max Douglas
Defining replication mechanisms at the telomere end

Dr Marco Gerlinger
Molecular mechanisms of acquired chemotherapy resistance in colorectal cancer and their implications for novel therapeutics development

Dr Sebastian Guettler
Conformational switches of AXIN in Wnt/Beta-catenin signalling

Professor Chris Jones
Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma

Dr Robin Jones
TRANS-CASPS: Translational studies in the Cediranib in Alveolar Soft Part Sarcoma (CASPS) trial.

Dr Astero Klampatsa
Characterisation and preclinical evaluation of a fibroblast-activating protein (FAP) targeted TRUCK CAR T-cell therapy for malignant pleural mesothelioma (MPM)

Professor Chris Lord and Professor Andrew Tutt
Understanding the homeostatic response to DNA repair inhibitors in breast cancer

Professor Pascal Meier
Winners versus Losers: Harnessing Cell Competition to kill tumour cells

Dr Wojciech Niedzwiedz
Systematic investigation of the mechanisms of replication fork protection, towards novel therapeutic strategy

Professor Nick Turner
Elucidating resistance to AKT inhibition in metastatic breast cancer

Dr Anderson Wang
Functional characterisation of DNA damage response deficiency in cancer

Professor Paul Workman, FRS
Understanding the regulation and impact of variant splicing in non-small cell lung cancer

Please apply via recruiter’s website.

Favorite